Terkko Navigator / Leppä, S(irpa)*

Checkpoint protein expression in the tumor microenvironment defines the outcome of classical Hodgkin lymphoma patients

Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma

Transformation and outcome of nodular lymphocyte predominant Hodgkin lymphoma: a Finnish Nationwide population-based study

Clinical Impact of Immune Cells and Their Spatial Interactions in Diffuse Large B-Cell Lymphoma Microenvironment

Testicular Diffuse Large B-Cell Lymphoma-Clinical, Molecular, and Immunological Features

Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma

Treatment response of colorectal cancer liver metastases to neoadjuvant or conversion therapy: a prospective multicentre follow-up study using MRI, diffusion-weighted imaging and ¹H-MR spectroscopy compared with histology (subg

Prognostic impact of soluble CD163 in patients with diffuse large B-cell lymphoma

Soluble PD-1 but Not PD-L1 Levels Predict Poor Outcome in Patients with High-Risk Diffuse Large B-Cell Lymphoma

Immunogenomic Landscape of Hematological Malignancies

Molecular background delineates outcome of double protein expressor diffuse large B-cell lymphoma

Low Absolute Lymphocyte Counts in the Peripheral Blood Predict Inferior Survival and Improve the International Prognostic Index in Testicular Diffuse Large B-Cell Lymphoma

Immunogenomic Landscape of Hematological Malignancies

Adverse prognostic impact of regulatory T-cells in testicular diffuse large B-cell lymphoma

Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis

Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series

Prognostic Impact of Tumor-Associated Macrophages on Survival Is Checkpoint Dependent in Classical Hodgkin Lymphoma

<em>STAT3</em> Mutation Is Associated with STAT3 Activation in CD30⁺ ALK^- ALCL

Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma

Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study

Drug screening approach combines epigenetic sensitization with immunochemotherapy in cancer

Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study

Pixantrone beyond monotherapy: a review

Distinct subtypes of diffuse large B-cell lymphoma defined by hypermutated genes

Intravenous but not intrathecal central nervous system-directed chemotherapy improves survival in patients with testicular diffuse large B-cell lymphoma

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

Clinical features and outcome of the patients with sinonasal tract diffuse large B-cell lymphoma in the pre-rituximab and rituximab eras

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma

PD-L1⁺ tumor-associated macrophages and PD-1⁺ tumor-infiltrating lymphocytes predict survival in primary testicular lymphoma

Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study

Identifying differentially methylated sites in samples with varying tumor purity

MicroRNAs regulate key cell survival pathways and mediate chemosensitivity during progression of diffuse large B-cell lymphoma

Clinical significance of gene defects in B-cell lymphomas

HIV infection and cancer

Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma

Alternative splicing discriminates molecular subtypes and has prognostic impact in diffuse large B-cell lymphoma

Clinical findings in 25 patients with sinonasal or nasopharyngeal extramedullary plasmacytoma in a four-decade single-centre series

Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2

Deltex-1 mutations predict poor survival in diffuse large B-cell lymphoma

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study

Plasma immunoprofiling of patients with high-risk diffuse large B-cell lymphoma: a Nordic Lymphoma Group study

FGF21 is a biomarker for mitochondrial translation and mtDNA maintenance disorders

Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial

Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma

Clinical findings of extranodal SNT lymphoid malignancies in a four-decade single-centre series

Total peroxiredoxin expression is associated with survival in patients with follicular lymphoma

Allogeneic Haematopoietic Stem Cell Transplantation for Patients with Cutaneous T-cell Lymphoma

Constant pattern of relapse in primary central nervous lymphoma patients treated with high-dose methotrexate combinations. A Finnish retrospective study